Hormonal
Tirzepatid (5-15 mg weekly) produces superior HbA1c reduction (mean 1.87-2.59%) and body weight loss (up to 12.9 kg) compared to placebo, semaglutide, and insulin in patients with type 2 diabetes.
Tirzepatid is a once-weekly injection for Type 2 Diabetes that significantly lowers blood sugar (HbA1c) and promotes substantial weight loss, outperforming other common diabetes medications like semaglutide and insulin. It works by mimicking two gut hormones (GIP and GLP-1). Common side effects like nausea are manageable and tend to improve over time. It is approved for adults with T2D, often used alongside metformin or other drugs.
Across the SURPASS-1 to -5 studies, all dose regimens of tirzepatide were associated with mean reductions in HbA1c of 1.87–2.59 % at either week 40 or 52 that were consistently significantly greater than changes seen in comparator groups. Tirzepatide showed superior effects on body weight reduction compared to all active comparators and placebo in these trials.
Why this rating
Based on multiple Phase 3 randomized controlled trials (SURPASS 1-5).
Source
Tirzepatid: GIP-/GLP-1-Rezeptoragonist zur Therapie des Typ-2-Diabetes – SURPASS-Studienprogramm
Jens Aberle et al. · Diabetologie und Stoffwechsel · 2023
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →